DEC 23, 2018 11:22 PM PST

Buruli ulcer: promising drug for a forgotten disease

WRITTEN BY: Nouran Amin

One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central Africa. Buruli ulcer is caused by the bacterium Mycobacterium ulcerans and results in devastating skin lesions leading to permanent disfigurement and long-term disabilities.

Treatment for the disease considers surgical removal of skin lesions as well as antibiotics involving the combination of oral rifampicin and injected streptomycin. However, these treatments come with many limitations. For one, surgery is often not an accessible option especially in in low-income areas. Furtherer, administration of antibiotics requires daily visits to a health center and antibiotic use is often plagued with great side-effects resulting such as hearing loss in over 20% of treated patients. These challenges are pushing researchers to seek safer, accessible, and effective treatment options.

Now, in a study published in Nature Communications, researchers have developed a promising compound against Buruli ulcer. The compound, referred to as Q203 (an imidazopyridine amide), was concluded to be highly effective against Buruli ulcer during in vitro and in vivo studies.

"We were very surprised when we saw this high activity. We had previously screened hundreds of compounds that were originally intended for TB drug development and none of the others showed promising activity against Mycobacterium ulcerans," said Gerd Pluschke, Head of the Molecular Immunology Unit at Swiss TPH. "Q203, however, is even more effective against Buruli ulcer than the current most active antibiotic rifampicin. Such a new and exquisitely effective drug combined with a second antibiotic may result in a considerably shorter oral treatment regimen with fewer adverse side effects."

A promising new drug candidate may improve treatment options of Buruli ulcer patients.

Credit: Hubert Vuagnat via Swiss Tropical and Public Health Institute

What makes Q203 very advantageous for treatment is it has already been tested in a phase I clinical trial for Tuberculous. "That means that as soon as funding can be secured, we will directly test the new compound in Buruli ulcer patients in a phase II trial," says Pluschke.

Source: Swiss Tropical and Public Health Institute

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 27, 2020
Cell & Molecular Biology
How Spiders May Open a Path to IBS Treatment
SEP 27, 2020
How Spiders May Open a Path to IBS Treatment
Irritable bowel syndrome (IBS) is term that describes a gut disorder that causes abdominal pain, cramping, diarrhea or c ...
OCT 21, 2020
Drug Discovery & Development
New ALS Treatment Extends Life for Several Months
OCT 21, 2020
New ALS Treatment Extends Life for Several Months
Currently, there are only two approved medications to treat Lou Gehrig's disease (also known as ALS), a condition po ...
OCT 09, 2020
Technology
Deep Learning Advances Drug Design
OCT 09, 2020
Deep Learning Advances Drug Design
Computational data is advancing all areas of medicine and pharmaceutical drug development is certainly no exception. &nb ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 06, 2020
Drug Discovery & Development
New Vaccine Shows Promise for Herpes
NOV 06, 2020
New Vaccine Shows Promise for Herpes
The World Health Organization estimates that over 500 million people have Herpes Simplex Virus Type 2 (HSV-2), a sexuall ...
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
Loading Comments...